Changes in Hong Kong stocks | Livzon Pharmaceuticals (01513) plummeted by more than 16% in the first half of the year, both revenue and net profit fell sharply, and the performance of chemical preparations and traditional Chinese medicine formulations declined sharply

The Zhitong Finance App learned that Lizhu Pharmaceutical (01513) plummeted by more than 16%. As of press release, it fell 16.05% to HK$20.92, with a turnover of HK$447.98 million.

According to the news, Livzon Pharmaceuticals announced its 2026 interim results. The group achieved operating income of about 5 billion yuan, a year-on-year decrease of 20.28%; net profit attributable to shareholders of the parent company was 932 million yuan, a year-on-year decrease of 27.23%; and basic income per share was 1.05 yuan. Looking at the specific business, the sharp decline in the performance of chemical preparations and traditional Chinese medicine formulations has become a major factor dragging down the company's overall revenue.

During the reporting period, the chemical formulation sector achieved sales revenue of 2,442 billion yuan, a year-on-year decrease of 25.33%, mainly due to the impact of medical insurance price cuts on products such as the iprazole sodium series and injectable urotropin, as well as the reduction in sales volume due to the implementation of the eleventh batch of national procurement of psychiatric products. The traditional Chinese medicine formulation and other sectors achieved sales revenue of 521 million yuan, a year-on-year decrease of 34.83%, due to a decline in the incidence of influenza and respiratory diseases in the country, leading to a decrease in revenue from related antiviral granules and diagnostic products.